Rheumatoid Arthritis

When the serum cotinine levels were below -2.756 ng/mL, each 1 ng/mL increase in log-2-transformed serum cotinine levels increased the RA risk by 16.3%.

Andrew Sharobeem, DO, discusses the major unmet needs among patients with Ehlers-Danlos Syndrome, including awareness among healthcare providers.

New analysis suggests use of high-dose etanercept may help children with juvenile idiopathic arthritis achieve remission and reduce disease activity.

This analysis may require further research to determine whether other treatment-resistant depression or severe depression definitions are specifically associated with inflammatory joint disease.

Patients with systemic autoimmune/inflammatory rheumatic diseases were nearly 3 times more likely to receive opioid prescriptions from 2006 to 2019.

A real-world study from Spain suggests baricitinib demonstrated favorable effectiveness, adherence, and safety in rheumatoid arthritis, but investigators caution more research is needed.

As disparate representation in pivotal research impacts the outcomes of common diseases like lupus, clinicians and researchers alike are working to foster trust and collaboration with more patients of color.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

Patients in the moderate and high disease activity cohorts reported significantly reduced health state utility values and HRQoL scores compared with the reference cohort.

A new study highlights the importance of daily antioxidant intake for endometriosis-related RA.

Lasso demonstrated advantages in predicting clinical remission in patients with RA treated with TNF, with a specificity of 69.9% and sensitivity of 61.7%.

Demographic, psychosocial, and clinical factors—along with patient-provider relationships—all impact medication adherence and patient satisfaction with RA treatment.

Internal dysbiosis was present in 66% of patients at baseline and was more common among those with a disease duration of > 2 years.

Patients with RA reported worse outcomes for all PROMs compared with CSA or UA.

Patients receiving abatacept experienced smaller increases in mean IMT, max IMT, and plaque score compared with the csDMARD cohorts.

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.

An extension study showed upadacitinib 15 mg and 30 mg for rheumatoid arthritis continues to be favorable, with many patients achieving remission.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.

Participants described the intervention as complete and coherent and would recommend this intervention to other patients.

S Louis Bridges Jr, MD, PhD, explores the role of artificial intelligence in managing rheumatoid arthritis.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

A study found MRI treat-to-target strategy does not help bring RA patients to remission, even when also targeting the absence of osteitis alongside clinical remission.

Five barriers to adopting TNF therapeutic drug monitoring emerged among a cohort of experienced rheumatologists.

The median survival for triple therapy was longer compared with double therapy (15.1 months vs 9.6 months).

Obesity was linked to a lower likelihood of obtaining response to treatment during the 48-week follow-up period.

Exercise was beneficial in functional status for both patients with RA and spondyloarthritis.

Birthweight was significantly lower in women who were not treated with a TNF.

Receiving methotrexate and leflunomide within the 3 months prior to conception was linked to an increased rate of adverse pregnancy outcomes.